TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.5.1 BOTTOM-UP APPROACH
3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
4.2.2 RISING DEMAND FOR PRECISION MEDICINE
4.2.3 INCREASING INVESTMENT IN NANOBODY RESEARCH AND DEVELOPMENT
4.3 RESTRAINTS
4.3.1 MANUFACTURING CHALLENGES AND HIGH PRODUCTION COSTS
4.4 OPPORTUNITY
4.4.1 GROWING DEVELOPMENT OF NEW APPLICATIONS OF NANOBODIES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL NANOBODY MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON CLINICAL TRIALS
5.3.3 IMPACT ON DEMAND AND SUPPLY
6 GLOBAL NANOBODY MARKET, BY TYPE
6.1 OVERVIEW
6.2 MONO-SPECIFIC
6.3 MULTI-SPECIFIC
7 GLOBAL NANOBODY MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 THERAPEUTIC
7.2.1 CANCER
7.2.2 NEURODEGENERATIVE DISEASES
7.2.3 INFECTIOUS DISEASES
7.2.4 OTHERS
7.3 DIAGNOSTIC
7.3.1 DETECTION OF PROTEINS AND MICROORGANISMS
7.3.2 DETECTION OF SMALL MOLECULES
7.3.3 IMAGING
7.4 RESEARCH
8 GLOBAL NANOBODY MARKET, BY END USER
8.1 OVERVIEW
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3 RESEARCH LABORATORIES
8.4 OTHERS
9 GLOBAL NANOBODY MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL NANOBODY MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL NANOBODY MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
10.6.2 MERGER/ ACQUISITION
10.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION
10.7 MAJOR PLAYERS SALES ANALYSIS
10.8 MAJOR PLAYERS R&D ANALYSIS
11 COMPANY PROFILES
11.1 SANOFI
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 MERCK KGAA
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 BIOCYTOGEN
11.3.1 COMPANY OVERVIEWS
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 PROTEINTECH GROUP, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 NOVARTIS AG
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTSS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 GENSCRIPT
11.6.1 COMPANY OVERVIEWS
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 SENSEI BIOTHERAPEUTICS, INC
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 BERONI GROUP
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 EXEVIR BIO
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
11.11 DIOSCURE THERAPEUTICS SE
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 GLOBAL NANOBDOY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 3 GLOBAL NANOBDOY MARKET, FOR MONO-SPECIFIC, BY REGION, 2019–2032 (USD BILLION)
TABLE 4 GLOBAL NANOBDOY MARKET, FOR MULTI-SPECIFIC, BY REGION, 2019–2032 (USD BILLION)
TABLE 5 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 6 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY REGION, 2019–2032 (USD BILLION)
TABLE 7 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 8 GLOBAL NANOBDOY MARKET, FOR CANCER, BY REGION, 2019–2032 (USD BILLION)
TABLE 9 GLOBAL NANOBDOY MARKET, FOR NEURODEGENERATIVE DISEASES, BY REGION, 2019–2032 (USD BILLION)
TABLE 10 GLOBAL NANOBDOY MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019–2032 (USD BILLION)
TABLE 11 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)
TABLE 12 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY REGION, 2019–2032 (USD BILLION)
TABLE 13 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 14 GLOBAL NANOBDOY MARKET, FOR DETECTION OF PROTEINS AND MICROORGANISMS, BY REGION, 2019–2032 (USD BILLION)
TABLE 15 GLOBAL NANOBDOY MARKET, FOR DETECTION OF SMALL MOLECULES, BY REGION, 2019–2032 (USD BILLION)
TABLE 16 GLOBAL NANOBDOY MARKET, FOR IMAGING, BY REGION, 2019–2032 (USD BILLION)
TABLE 17 GLOBAL NANOBDOY MARKET, FOR RESEARCH, BY REGION, 2019–2032 (USD BILLION)
TABLE 18 GLOBAL NANOBDOY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 19 GLOBAL NANOBDOY MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2032 (USD BILLION)
TABLE 20 GLOBAL NANOBDOY MARKET, FOR RESEARCH LABORATORIES, BY REGION, 2019–2032 (USD BILLION)
TABLE 21 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)
TABLE 22 GLOBAL: NANOBODY MARKET, BY REGION, 2019–2032 (USD BILLION)
TABLE 23 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY, 2019–2032 (USD BILLION)
TABLE 24 NORTH AMERICA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 25 NORTH AMERICA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 26 NORTH AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 27 NORTH AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 28 NORTH AMERICA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 29 US: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 30 US: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 31 US: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 32 US: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 33 US: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 34 CANADA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 35 CANADA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 36 CANADA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 37 CANADA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 38 CANADA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 39 EUROPE: NANOBODY MARKET, BY COUNTRY, 2019–2032 (USD BILLION)
TABLE 40 EUROPE: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 41 EUROPE: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 42 EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 43 EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 44 EUROPE: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 45 GERMANY: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 46 GERMANY: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 47 GERMANY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 48 GERMANY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 49 GERMANY: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 50 UK: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 51 UK: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 52 UK: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 53 UK: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 54 UK: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 55 FRANCE: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 56 FRANCE: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 57 FRANCE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 58 FRANCE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 59 FRANCE: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 60 ITALY: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 61 ITALY: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 62 ITALY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 63 ITALY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 64 ITALY: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 65 SPAIN: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 66 SPAIN: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 67 SPAIN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 68 SPAIN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 69 SPAIN: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 70 REST OF EUROPE: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 71 REST OF EUROPE: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 72 REST OF EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 73 REST OF EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 74 REST OF EUROPE: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 75 ASIA PACIFIC: NANOBODY MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
TABLE 76 ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 77 ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 78 ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 79 ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 80 ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 81 JAPAN: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 82 JAPAN: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 83 JAPAN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 84 JAPAN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 85 JAPAN: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 86 CHINA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 87 CHINA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 88 CHINA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 89 CHINA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 90 CHINA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 91 INDIA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 92 INDIA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 93 INDIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 94 INDIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 95 INDIA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 96 SOUTH KOREA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 97 SOUTH KOREA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 98 SOUTH KOREA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 99 SOUTH KOREA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 100 SOUTH KOREA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 101 AUSTRALIA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 102 AUSTRALIA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 103 AUSTRALIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 104 AUSTRALIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 105 AUSTRALIA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 106 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 107 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 108 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 109 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 110 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 111 REST OF THE WORLD: NANOBODY MARKET, BY REGION, 2019-2032(USD BILLION)
TABLE 112 REST OF THE WORLD: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 113 REST OF THE WORLD: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 114 REST OF THE WORLD: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 115 REST OF THE WORLD: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 116 REST OF THE WORLD: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 117 MIDDLE EAST: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 118 MIDDLE EAST: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 119 MIDDLE EAST: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 120 MIDDLE EAST: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 121 MIDDLE EAST: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 122 AFRICA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 123 AFRICA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 124 AFRICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 125 AFRICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 126 AFRICA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 127 LATIN AMERICA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)
TABLE 128 LATIN AMERICA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 129 LATIN AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 130 LATIN AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)
TABLE 131 LATIN AMERICA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)
TABLE 132 MAJOR PLAYERS IN THE GLOBAL NANOBODY MARKET
TABLE 133 MOST ACTIVE PLAYER IN THE GLOBAL NANOBODY MARKET
TABLE 134 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 135 MERGER/ ACQUISITION
TABLE 136 PARTNERSHIP/ AGREEMENT/COLLABORATION
TABLE 137 SANOFI: PRODUCTS OFFERED
TABLE 138 SANOFI: KEY DEVELOPMENTS
TABLE 139 MERCK KGAA: PRODUCTS OFFERED
TABLE 140 MERCK KGAA: KEY DEVELOPMENTS
TABLE 141 BIOCYTOGEN: PRODUCTS OFFERED
TABLE 142 BIOCYTOGEN: KEY DEVELOPMENTS
TABLE 143 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED
TABLE 144 NOVARTIS AG: PRODUCTS OFFERED
TABLE 145 GENSCRIPT: PRODUCTS OFFERED
TABLE 146 SENSEI BIOTHERAPEUTICS: PRODUCTS OFFERED
TABLE 147 SENSEI BIOTHERAPEUTICS: KEY DEVELOPMENTS
TABLE 148 BERONI GROUP: PRODUCTS OFFERED
TABLE 149 BERONI GROUP: KEY DEVELOPMENTS
TABLE 150 EXEVIR BIO BV.: PRODUCTS OFFERED
TABLE 151 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: PRODUCTS OFFERED
TABLE 152 DIOSCURE THERAPEUTICS SE: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL NANOBODY MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: GLOBAL NANOBODY MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS OF THE GLOBAL NANOBODY MARKET
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NANOBODY MARKET
FIGURE 9 GLOBAL NANOBODY MARKET, TYPE SEGMENT ATTRACTIVENESS, (USD BILLION)
FIGURE 10 GLOBAL NANOBDOY MARKET, BY TYPE, 2022 & 2032 (USD BILLION)
FIGURE 11 GLOBAL NANOBDOY MARKET SHARE (%), BY TYPE, 2022
FIGURE 12 GLOBAL NANOBODY MARKET, APPLICATION SEGMENT ATTRACTIVENESS, (USD BILLION)
FIGURE 13 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2022 & 2032 (USD BILLION)
FIGURE 14 GLOBAL NANOBDOY MARKET SHARE (%), BY APPLICATION, 2022
FIGURE 15 GLOBAL NANOBODY MARKET, END USER SEGMENT ATTRACTIVENESS, (USD BILLION)
FIGURE 16 GLOBAL NANOBDOY MARKET, BY END USER, 2022 & 2032 (USD BILLION)
FIGURE 17 GLOBAL NANOBDOY MARKET SHARE (%), BY END USER, 2022
FIGURE 18 GLOBAL: NANOBODY MARKET, BY REGION 2022 & 2032 (USD BILLION)
FIGURE 19 GLOBAL: NANOBODY MARKET SHARE (%), BY REGION, 2022
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)
FIGURE 21 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY 2022 & 2032 (USD BILLION)
FIGURE 22 NORTH AMERICA: NANOBODY MARKET SHARE (%), BY COUNTRY 2022
FIGURE 23 EUROPE MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)
FIGURE 24 EUROPE: NANOBODY MARKET, BY COUNTRY 2022 & 2032 (USD BILLION)
FIGURE 25 EUROPE: NANOBODY MARKET SHARE (%), BY COUNTRY 2022
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)
FIGURE 27 ASIA PACIFIC NANOBODY MARKET SHARE, BY COUNTRY 2022 & 2032 (USD BILLION)
FIGURE 28 ASIA PACIFIC: NANOBODY MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)
FIGURE 30 REST OF THE WORLD NANOBODY MARKET SHARE, BY REGION 2022 & 2032 (USD BILLION)
FIGURE 31 REST OF THE WORLD: NANOBODY MARKET SHARE (%), BY REGION, 2022
FIGURE 32 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 33 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL NANOBODY MARKET
FIGURE 34 GLOBAL NANOBODY MARKET: COMPETITIVE LANDSCAPE
FIGURE 35 MAJOR PLAYERS SALES, 2022 (USD BILLION)
FIGURE 36 MAJOR PLAYER R&D EXPENDITURE, 2022 (USD BILLION)
FIGURE 37 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 SANOFI: SWOT ANALYSIS
FIGURE 39 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 MERCK KGAA: SWOT ANALYSIS
FIGURE 41 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 NOVARTIS AG: SWOT ANALYSIS
FIGURE 43 GENSCRIPT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 GENSCRIPT: SWOT ANALYSIS
FIGURE 45 SENSEI BIOTHERAPEUTICS: SWOT ANALYSIS
FIGURE 46 BERONI GROUP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: FINANCIAL OVERVIEW SNAPSHOT